Recognizing that every minute lost during a stroke equates to 1.9 million brain cells lost, Time Is Brain addresses this critical issue with a solution that improves treatment speed and outcomes.
Their innovative portable medical device, BraiN20® is set to transform the landscape of stroke management by offering faster and more accurate treatment options. By reducing the time to treatment and enhancing the effectiveness of EVT, Time Is Brain aims to significantly improve patient outcomes and save countless brain cells.
Currently, it is in a pre-industrialization state after the technology has been validated in several hospitals in Spain.
- Pilots: In 5 hospitals: Germans Trias i Pujol, Bellvitge, Clínic or Trueta.
- Maturity: Pre-industrialization
- Market size: 200M€
- Capital raised: 1,7M €
- Company Valuation: 7,9 M€
- Open Round: Yes
The technology of the BraiN20® device uses artificial intelligence to automatically record and analyze the N20 signal. This information reduces time-to-treatment, from 4 hours to just 1 hour, and boosts the efficacy of EVT (Endovascular thrombectomy), allowing a taylor management for each patient while providing specialists with real-time insights during and after procedures.
- Sector: Health tech
- Country: Spain
- Nº of workers: 12
